Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6NCya-Btnl9em1/Cya
Common Name:
Btnl9-KO
Product ID:
S-KO-06909
Background:
C57BL/6NCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Btnl9-KO
Strain ID
KOCMP-237754-Btnl9-B6N-VA
Gene Name
Btnl9
Product ID
S-KO-06909
Gene Alias
B430208I01; Btn3; D330012D11Rik
Background
C57BL/6NCya
NCBI ID
237754
Modification
Conventional knockout
Chromosome
11
Phenotype
MGI:2442439
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6NCya-Btnl9em1/Cya mice (Catalog S-KO-06909) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000046522
NCBI RefSeq
NM_172793
Target Region
Exon 3~5
Size of Effective Region
~5.2 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Btnl9, or butyrophilin-like protein 9, is a member of the immunoglobulin families. It has been implicated in immune-related and cancer-related pathways [1]. In some cancers, its role seems to be associated with tumor-suppressive functions, potentially influencing tumor progression, immune cell infiltration, and prognosis.

In thyroid cancer (THCA), BTNL9 expression is down-regulated, and low expression is associated with a poorer progression-free interval. It shows stronger H3K27ac modifications in benign thyroid nodule tissues compared to papillary thyroid cancer tissues, indicating its possible role in tumorigenesis [1]. In breast cancer, BTNL9 expression is declined, and ectopic expression inhibits cell proliferation, colony formation, and metastasis, while knockdown has the opposite effect. It blocks breast cancer cells in the G2/M phase via the P53/CDC25C and P53/GADD45 pathways [2]. In non-small-cell lung cancer, lncRNA CALML3-AS1 inhibits BTNL9 transcription and expression, and BTNL9 down-regulation counteracts the antitumor effects of CALML3-AS1 depletion, suggesting its importance in NSCLC progression [3]. In uveal melanoma, high expression of BTNL9 is associated with a favorable prognosis, and it can suppress invasion but not proliferation [5]. In lung adenocarcinoma, BTNL9 expression is down-regulated and is associated with a poor probability of overall survival, and its expression is positively correlated with immune cell infiltration levels [6]. In pancreatic cancer, decreased expression of BTNL9 is associated with a reduced survival rate [7]. In BRAF-mutated peritoneal metastasis from colorectal cancer, increased expression of BTNL9 is observed, and drugs targeting BTN immune checkpoints could be a novel therapy approach [8]. In addition, a stop-gain variant in BTNL9 is associated with atherogenic lipid profiles in Polynesian populations [4], and there is a negative correlation between BTNL9 and the risk of amyotrophic lateral sclerosis [9]. In breast cancer, the expression of BTNL9 as one of the immune checkpoint genes was investigated, and its prognostic value was analyzed among different subtypes [10].

In conclusion, BTNL9 appears to play a crucial role in multiple biological processes, especially in cancer-related events such as tumor progression, metastasis, and prognosis. Its dysregulation is associated with various cancers, lipid-related disorders, and neurodegenerative diseases. The study of BTNL9 through different research models helps to understand its biological functions and provides potential biomarker and therapeutic target implications for these diseases.

References:

1. Zhang, Luyao, Yu, Shuang, Hong, Shubin, Li, Yanbing, Xiao, Haipeng. 2023. Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer. In BMC medical genomics, 16, 234. doi:10.1186/s12920-023-01676-8. https://pubmed.ncbi.nlm.nih.gov/37798795/

2. Mo, Qingfan, Xu, Ke, Luo, Chenghao, Wang, Long, Ren, Guosheng. 2021. BTNL9 is frequently downregulated and inhibits proliferation and metastasis via the P53/CDC25C and P53/GADD45 pathways in breast cancer. In Biochemical and biophysical research communications, 553, 17-24. doi:10.1016/j.bbrc.2021.03.022. https://pubmed.ncbi.nlm.nih.gov/33756341/

3. Zhang, Heng, Wang, Shao-Qiang, Zhu, Jie-Bo, Duan, Chao-Jun, Zhang, Chun-Fang. 2023. LncRNA CALML3-AS1 modulated by m6A modification induces BTNL9 methylation to drive non-small-cell lung cancer progression. In Cancer gene therapy, 30, 1649-1662. doi:10.1038/s41417-023-00670-7. https://pubmed.ncbi.nlm.nih.gov/37884580/

4. Carlson, Jenna C, Krishnan, Mohanraj, Rosenthal, Samantha L, Weeks, Daniel E, Minster, Ryan L. 2022. A stop-gain variant in BTNL9 is associated with atherogenic lipid profiles. In HGG advances, 4, 100155. doi:10.1016/j.xhgg.2022.100155. https://pubmed.ncbi.nlm.nih.gov/36340932/

5. Jiang, Zhongming, Liu, Fei. 2019. Butyrophilin-Like 9 (BTNL9) Suppresses Invasion and Correlates with Favorable Prognosis of Uveal Melanoma. In Medical science monitor : international medical journal of experimental and clinical research, 25, 3190-3198. doi:10.12659/MSM.914074. https://pubmed.ncbi.nlm.nih.gov/31039142/

6. Ma, Weishuang, Liang, Jiaming, Mo, Junjian, Tian, Dongbo, Chen, Zisheng. 2021. Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma. In BMC cancer, 21, 1096. doi:10.1186/s12885-021-08790-9. https://pubmed.ncbi.nlm.nih.gov/34635082/

7. Khojasteh-Leylakoohi, Fatemeh, Mohit, Reza, Khalili-Tanha, Nima, Batra, Jyotsna, Avan, Amir. 2023. Down regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer. In Scientific reports, 13, 16678. doi:10.1038/s41598-023-42928-y. https://pubmed.ncbi.nlm.nih.gov/37794108/

8. Lund-Andersen, Christin, Torgunrud, Annette, Kanduri, Chakravarthi, Larsen, Stein G, Flatmark, Kjersti. 2024. Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer. In Journal of translational medicine, 22, 646. doi:10.1186/s12967-024-05467-2. https://pubmed.ncbi.nlm.nih.gov/38982444/

9. Lu, Chuan, Huang, Xiao-Xiao, Huang, Ming, Liu, Chaoning, Xu, Jianwen. 2025. Mendelian randomization of plasma proteomics identifies novel ALS-associated proteins and their GO enrichment and KEGG pathway analyses. In BMC neurology, 25, 82. doi:10.1186/s12883-025-04091-x. https://pubmed.ncbi.nlm.nih.gov/40033250/

10. Fang, Jun, Chen, Feng, Liu, Dong, Chen, Zhigang, Wang, Yuezhen. . Prognostic value of immune checkpoint molecules in breast cancer. In Bioscience reports, 40, . doi:10.1042/BSR20201054. https://pubmed.ncbi.nlm.nih.gov/32602545/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest